Source: Anne McMillin University of Nevada,Micromet Presents Data at AACR Meeting Show Elimination of colon cancer stem cells by BiTE antibody MT110Micromet , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, data Annual Meeting of the Annual Meeting of the American Association for Cancer Research in Denver, Colorado, that its BiTE antibody MT110 can eliminate cancer stem cells . Cancer stem cells are thought to be responsible for resistance of human cancers to chemotherapy and for metastatic relapse. MT110 is in a phase 1 clinical – in patients with in patients with lung or gastrointestinal cancer viagra.com .
Maetzel, 11: 62-171 About Micromet – Micromet Thecal company based in Bethesda, and Munich, Germany. The company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The novel antibody technology is based on its proprietary BiTE antibody platform, a new class of antibodies that specifically activate T cells from the patient ‘s own immune system is based , the cancer cells or other disease eliminate merged cells. Four of the Company antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. Society lead program is a BiTE antibody known blinatumomab or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin’s lymphoma. Micromet’s second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule . The Company owns all rights to MT110, Micromet a Phase 1 clinical trial for the treatment of patients with solid tumors. Society third Phase Antibody Adecatumumab also as MT201, a traditional human monoclonal antibody which targets EpCAM expression known solid tumors. Micromet licensed a quarter of the clinical phase antibody MT293, to TRACON Pharmaceuticals, MT293 in a phase in a phase 1 clinical trial for the treatment of patients with cancer. The company develops preclinical programs include MT203 in collaboration with Nycomed. MT203 is a traditional human antibody to neutralize the activity of granulocyte / macrophage colony – stimulating factor , the potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis and has. Micromet has an exclusive option to Bayer Schering Pharma AG, Forward Looking StatementsTE antibody against an undisclosed solid tumor target License. Additional BiTE antibodies, targeting CEA, EGFR and MCSP or are in various stages of preclinical development.